Jerusalem G - Search Results

1

¹⁸F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers.

Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, Mievis F, Aerts J, Waltregny D, Jerusalem G, Hustinx R. Withofs N, et al. Among authors: jerusalem g. Nucl Med Commun. 2011 Mar;32(3):168-76. doi: 10.1097/MNM.0b013e3283412ef5. Nucl Med Commun. 2011. PMID: 21076343 Free article. Clinical Trial.

2

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Rigo P, et al. Among authors: jerusalem g. Eur J Nucl Med. 1996 Dec;23(12):1641-74. doi: 10.1007/BF01249629. Eur J Nucl Med. 1996. PMID: 8929320 Free article. Review.

3

Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases.

Hustinx R, Paulus P, Jacquet N, Jerusalem G, Bury T, Rigo P. Hustinx R, et al. Among authors: jerusalem g. Ann Oncol. 1998 Apr;9(4):397-401. doi: 10.1023/a:1008290027419. Ann Oncol. 1998. PMID: 9636830 Free article. Clinical Trial.

4

Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.

Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, Rigo P. Jerusalem G, et al. Nucl Med Commun. 1999 Jan;20(1):13-20. doi: 10.1097/00006231-199901000-00004. Nucl Med Commun. 1999. PMID: 9949408

5

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL).

Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, Fillet G. Jerusalem G, et al. Ann Oncol. 2001 Jun;12(6):825-30. doi: 10.1023/a:1011169332265. Ann Oncol. 2001. PMID: 11484959 Free article. Clinical Trial.

6

Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).

Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P. Najjar F, et al. Among authors: jerusalem g. Cancer Biother Radiopharm. 2001 Aug;16(4):297-304. doi: 10.1089/108497801753131372. Cancer Biother Radiopharm. 2001. PMID: 11603000

7

Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.

Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, Rigo P, Green A. Belhocine T, et al. Among authors: jerusalem g. Clin Cancer Res. 2002 Sep;8(9):2766-74. Clin Cancer Res. 2002. PMID: 12231515 Clinical Trial.

8

The value of positron emission tomography (PET) imaging in disease staging and therapy assessment.

Jerusalem G, Hustinx R, Beguin Y, Fillet G. Jerusalem G, et al. Ann Oncol. 2002;13 Suppl 4:227-34. doi: 10.1093/annonc/mdf664. Ann Oncol. 2002. PMID: 12401695 Free article. Review. No abstract available.

9

Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease.

Jerusalem G, Beguin Y, Fassotte MF, Belhocine T, Hustinx R, Rigo P, Fillet G. Jerusalem G, et al. Ann Oncol. 2003 Jan;14(1):123-30. doi: 10.1093/annonc/mdg011. Ann Oncol. 2003. PMID: 12488304 Free article.

10

[End of treatment evaluation in patients with aggressive non-Hodgkin's lymphoma].

Warland V, Jérusalem G, Hustinx R, Beguin Y, Silvestre RM, Fassotte MF, Foidart-Willems J, Fillet G. Warland V, et al. Among authors: jerusalem g. Rev Med Liege. 2002 Dec;57(12):779-84. Rev Med Liege. 2002. PMID: 12632835 Free article. Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

287 results

Search Page

Filters